Eiger BioPharmaceuticals Inc (EIGRQ)

OTCMKTS: EIGRQ · Delayed Price · USD
2.100
-0.070 (-3.23%)
May 24, 2024, 4:00 PM EDT - Market closed
Market Cap 3.10M
Revenue (ttm) 15.77M
Net Income (ttm) -74.96M
Shares Out 1.48M
EPS (ttm) -50.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 5,150
Open 2.180
Previous Close 2.170
Day's Range 2.050 - 2.410
52-Week Range 1.610 - 4.000
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About EIGRQ

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development of therapies for hepatitis delta virus (HDV) and other serious diseases. The company offers Zokinvy for the treatment of Hutchinson-Gilford progeria syndrome and Processing-Deficient Progeroid Laminopathies. Its product candidates include Lonafarnib, an orally available, farnesylation inhibitor, which has completed Phase 3 clinical trials for HDV infection; Peginterferon Lambda (lambda), which is in clinical development for HDV; lambda, that... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 25
Stock Exchange OTCMKTS
Ticker Symbol EIGRQ
Full Company Profile

Financial Performance

In 2023, EIGRQ's revenue was $15.77 million, an increase of 16.98% compared to the previous year's $13.48 million. Losses were -$74.96 million, -22.54% less than in 2022.

Financial numbers in USD Financial Statements

News

Healthcare stocks fade as obesity-drug optimism fades

Healthcare companies fell sharply Monday as ebullience about a new class of weight control drugs subsided.

Other symbols: NVOVKTX
2 months ago - Market Watch

Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection

Announces “Stalking Horse” Agreement for the Sale of Zokinvy ® (lonafarnib) Patient Access to Zokinvy ® to Continue Uninterrupted PALO ALTO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Eiger BioPharmac...

2 months ago - GlobeNewsWire

Eiger and Partner, AnGes, Receive Approval for Zokinvy® (lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan

Clinical trial data demonstrated Zokinvy treatment extended life by an average of 4.3 years in children and young adults with Hutchinson-Gilford progeria Eiger to receive $500,000 approval milestone p...

4 months ago - PRNewsWire

Eiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse Stock Split

PALO ALTO, Calif. , Jan. 4, 2024 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) (the "Company"), a commercial-stage biopharmaceutical company focused on the development of innovative the...

5 months ago - PRNewsWire

Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

Resources prioritized to advance avexitide in hyperinsulinemic hypoglycemia indications Phase 3 LIMT-2 study of peginterferon lambda in chronic hepatitis delta discontinued due to safety findings Comp...

7 months ago - PRNewsWire

Eiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta

PALO ALTO, Calif., Sept. 12, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare...

9 months ago - PRNewsWire

Eiger BioPharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference

PALO ALTO, Calif. , Sept. 5, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare...

9 months ago - PRNewsWire

Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

Resources prioritized to advance avexitide in hyperinsulinemic hypoglycemia indications Active discussions underway with potential partners to advance late-stage virology programs Reduction in workfor...

10 months ago - PRNewsWire

Eiger BioPharmaceuticals to Focus on Metabolic Diseases with Avexitide; David Apelian Takes Helm as CEO

Prioritizing resources to advance avexitide in hyperinsulinemic hypoglycemia indications Active discussions underway with potential partners to advance late-stage virology programs Reduction in workfo...

11 months ago - PRNewsWire

Eiger BioPharmaceuticals to Host Business Update Call Tomorrow

Company to host conference call and live webcast on Thursday, June 29, at 8:30 am ET PALO ALTO, Calif. , June 28, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage...

11 months ago - PRNewsWire

Eiger BioPharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

Phase 3 HDV D-LIVR (lonafarnib/ritonavir) Study: Pre-NDA Meeting with FDA in Q2 Phase 3 HDV LIMT-2 (peginterferon lambda) Study: Complete Randomization in Q2 Phase 3 HI AVANT (avexitide) Program: Star...

1 year ago - PRNewsWire

Eiger BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

PALO ALTO, Calif. , May 3, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepat...

1 year ago - PRNewsWire

Eiger BioPharmaceuticals Strengthens Management Team with New Appointments

PALO ALTO, Calif., April 13, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepa...

1 year ago - PRNewsWire

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Phase 3 HDV D-LIVR (lonafarnib/ritonavir) Study: Pre-NDA Meeting Planned by End of Q2 Phase 3 HDV LIMT-2 (peginterferon lambda) Study: On Track to Complete Randomization by End of Q2 Phase 3 HI AVANT ...

1 year ago - PRNewsWire

New England Journal of Medicine Publishes Positive Phase 3 TOGETHER Results with Peginterferon Lambda in COVID-19

-  Phase 3 TOGETHER data showed early treatment with a single dose of peginterferon lambda (Lambda) in patients with mild-to-moderate COVID-19 infections resulted in significantly decreased clinical e...

1 year ago - PRNewsWire

7 Cheap But Risky Biotech Stocks

Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF drop nearly 50%.

Other symbols: AFMDBCABIMRXNKTXTIL
1 year ago - Barrons

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Eiger BioPharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - January 9, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Eiger BioPharma...

1 year ago - Newsfile Corp

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Eiger Investors of a Lead Plaintiff Deadline of January 9, 2023

NEW YORK , Jan. 9, 2023 /PRNewswire/ -- Attention Eiger BioPharmaceuticals, Inc. ("Eiger") (NASDAQ: EIGR) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenc...

1 year ago - PRNewsWire

EIGR FINAL DEADLINE NOTICE: ROSEN, A LEADING NATIONAL FIRM, Encourages Eiger BioPharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important January 9 Deadline in Securities Class Action - EIGR

New York, New York--(Newsfile Corp. - January 6, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) b...

1 year ago - Newsfile Corp

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Eiger BioPharmaceuticals, Inc. (EIGR)

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming January 9, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of inves...

1 year ago - Business Wire

Eiger Class Action: Levi & Korsinsky Reminds Eiger BioPharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2023 - EIGR

New York, New York--(Newsfile Corp. - January 6, 2023) - Levi & Korsinsky, LLP notifies investors in Eiger BioPharmaceuticals, Inc. ("Eiger" or the "Company") (NASDAQ: EIGR) of a class action securiti...

1 year ago - Newsfile Corp

DEADLINE MONDAY ALERT: The Schall Law Firm Encourages Investors in Eiger BioPharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - January 6, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Eiger BioPharma...

1 year ago - Newsfile Corp

EIGR SHAREHOLDER ALERT: Jakubowitz Law Reminds Eiger Shareholders of a Lead Plaintiff Deadline of January 9, 2023

NEW YORK , Jan. 6, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR). ...

1 year ago - PRNewsWire

MONDAY DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Eiger BioPharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - January 5, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Eiger BioPharma...

1 year ago - Newsfile Corp

EIGR LAWSUIT ALERT: Levi & Korsinsky Notifies Eiger BioPharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK , Jan. 5, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Eiger BioPharmaceuticals, Inc. ("Eiger" or the "Company") (NASDAQ: EIGR) of a class action securities lawsuit. CLASS...

1 year ago - PRNewsWire